Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
PANORAMIC virology-sub-study showing increased viral persistence with molnupiravir treatment. Molnupiravir 800mg twice daily for 5 days led to faster initial viral decline but 86% still had detectable virus by day 5. By day 14, molnupiravir was associated with significantly higher proportions with detectable virus and lower anti-spike antibodies compared to usual care. Serial genome sequencing revealed substantially increased mutagenesis with molnupiravir. Viable virus was cultured from samples up to 9 days post-treatment.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Chamod, Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zhou, Zibat. Multiple analyses have identified variants potentially created by molnupiravir Fountain-Jones, Kosakovsky Pond, Sanderson, .
viral culture+, 103.4% higher, RR 2.03, p = 0.33, treatment 6 of 117 (5.1%), control 3 of 119 (2.5%), days 6-20.
|
viral culture+, 31.1% lower, RR 0.69, p = 0.11, treatment 26 of 249 (10.4%), control 52 of 343 (15.2%), NNT 21, days 2-5.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Standing et al., 23 Feb 2024, Randomized Controlled Trial, United Kingdom, peer-reviewed, 54 authors, study period March 2022 - April 2022, trial
ISRCTN30448031.
Contact:
j.standing@ucl.ac.uk.
Abstract: Article
https://doi.org/10.1038/s41467-024-45641-0
Randomized controlled trial of molnupiravir
SARS-CoV-2 viral and antibody response in
at-risk adult outpatients
Received: 4 August 2023
A list of authors and their affiliations appears at the end of the paper
1234567890():,;
1234567890():,;
Accepted: 26 January 2024
Check for updates
Viral clearance, antibody response and the mutagenic effect of molnupiravir
has not been elucidated in at-risk populations. Non-hospitalised participants
within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir
(n = 253) or Usual Care (n = 324) were recruited to study viral and antibody
dynamics and the effect of molnupiravir on viral whole genome sequence from
1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is
detectable by Day 5 in most cases. At Day 14 (9 days post-treatment), molnupiravir is associated with significantly higher viral persistence and significantly
lower anti-SARS-CoV-2 spike antibody titres compared to Usual Care. Serial
sequencing reveals increased mutagenesis with molnupiravir treatment. Persistence of detectable viral RNA at Day 14 in the molnupiravir group is associated with higher transition mutations following treatment cessation. Viral
viability at Day 14 is similar in both groups with post-molnupiravir treated
samples cultured up to 9 days post cessation of treatment. The current 5-day
molnupiravir course is too short. Longer courses should be tested to reduce
the risk of potentially transmissible molnupiravir-mutated variants being
generated. Trial registration: ISRCTN30448031
Treatment of SARS-CoV-2 with the nucleoside analogue molnupiravir
(MK4482, EIDD2801) was reported to reduce viral load, hospitalisation
and mortality in unvaccinated participants with early COVID-19 in the
MOVeOUT trial1,2. Based on these data, molnupiravir received emergency use authorisation in the UK in November 2021 for early treatment of SARS-CoV-2 in individuals deemed to be at higher risk of
complications due to age or underlying comorbidities.
Molnupiravir is metabolised intracellularly to NHC-triphosphate,
which competes with natural cytidine and uridine for incorporation by
the viral RNA-dependent RNA polymerase (RdRp) into the nascent viral
RNA. This leads to abnormal, non-Watson-Crick pairing with guanosine
and uridine in further rounds of replication, increasing the substitution
of adenosine for guanosine and cytosine for uridine, so-called transition mutations, within the SARS-CoV-2 genome. Lethal mutagenesis
resulting from treatment with RdRp inhibitors eventually leads to viral
extinction3,4. A distinctive pattern of transition mutagenesis is evident
in viral genomes recovered from animals and humans who have
received molnupiravir3–5. The risk that, following molnupiravir treatment, some highly mutated viruses might remain viable and capable of
onward transmission has been postulated6,7.
To measure the impact of molnupiravir in a largely vaccinated
population, the Platform Adaptive trial of NOvel antiviRals for eArly
treatMent of covid-19 In the Community (PANORAMIC) was established. The first drug tested in PANORAMIC was molnupiravir, and
amongst 25,783 mostly vaccinated individuals, found that molnupiravir did not reduce hospitalisation or death8 (primary endpoint). Secondary outcomes showed those receiving molnupiravir experienced
significantly reduced viral load during treatment and reported faster
symptom recovery and fewer general..
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit